TMOD
Live / Applied — Fifth extension granted (statement of use) (as of 11 Aug 2025)
What this means for you
Not registered yet, but its 09 Dec 2020 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 90370290
- Mark type
- Stylized text
- Filed
- 09 Dec 2020
- Published for opposition
- 27 Sept 2022
- Attorney of record
- Joi A. White
Goods and services
- Class 005 — Pharmaceuticals: pharmaceutical products for the treatment and prevention of cancer and inflammatory diseases; therapeutic targets, namely, proteins or protein complexes, for the treatment and prevention of cancer, inflammation and inflammatory diseases; therapeutic cells, therapeutic proteins and therapeutic antibodies for human use for the treatment and prevention of cancer, inflammation and inflammatory diseases; therapeutics and cell therapies in the nature of proteins and protein complexes for the treatment of cancer, inflammation, and inflammatory diseases; engineered cell therapies in the nature of proteins and protein complexes for medical purposes, namely, the treatment and prevention of cancer, inflammation and inflammatory diseases; engineered cell therapy platforms consisting of modified cells, cell receptors, proteins and protein complexes; cell platforms consisting of modified cells, cell receptors, proteins and protein complexes for the treatment and prevention of cancer, inflammation and inflammatory diseases; biological technology platforms consisting of modified cells, cell receptors, proteins and protein complexes for developing and engineering therapeutic cells, therapeutic proteins, therapeutic antibodies, therapeutics and cellular therapies for the treatment and prevention of cancer, inflammation, and inflammatory diseases; cell platform consisting of modified cells, cell receptors, proteins and protein complexes for autologous and allogeneic cell manufacturing; therapeutics and cell therapies in the nature of proteins and protein complexes targeting targets lost in tumors for the treatment and prevention of cancer, inflammation and inflammatory diseases; gene therapy products, namely, genetically engineered tissues for transplant purposes
- Class 040 — Treatment of materials: custom manufacturing of cells, therapeutics and cell therapies for the treatment and prevention of cancer, inflammation and inflammatory diseases; biomanufacturing for others, namely, manufacturing of cells, therapeutics and cell therapeies for the treatment and prevention of cancer, inflammation and inflammatory diseases using biological cells in the manufacturing process; cell therapy manufacturing for others; autologous and allogeneic cell manufacturing for others; manufacturing services for others in the fields of therapeutics, cell therapies, biologics, medicine, and pharmaceuticals; providing technical information in the field of pharmaceutical manufacturing; custom manufacturing of biological cells, proteins, and antibodies for others for treatment and prevention of cancer, inflammation and inflammatory disease
- Class 042 — Scientific and technological services: Identification and development of, therapeutic targets, namely, proteins and protein complexes, for others for the treatment and prevention of cancer, inflammation and inflammatory diseases; development of therapeutics and cell therapies for the treatment and prevention of cancer, inflammation, and inflammatory diseases; development of therapeutics and cell therapies targeting targets lost in tumors for the treatment and prevention of cancer, inflammation and inflammatory diseases; biotechnology research, development, testing and analysis for the treatment of cancer, inflammation, and inflammatory diseases; scientific research and development services; providing scientific information in the fields of treatment and prevention of cancer, inflammation and inflammatory diseases; research, development, engineering and testing services in the fields of therapeutics, cell therapies, biologics, medicine, and pharmaceuticals; medical laboratory services, namely, tissue material processing and analysis in the field of autologous and allogeneic biologic preparations for medical use; biotechnology laboratory services; scientific and medical laboratory services; genetic engineering services; engineering of biological cells, cellular targets, proteins, and antibodies for others
Owner
- A2 Biotherapeutics, Inc., Agoura Hills, CA, US
- A2 Biotherapeutics, Inc., Agoura Hills, CA, US
Prosecution history
- 24 Nov 2025 — TEAS STATEMENT OF USE RECEIVED
- 12 Aug 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 11 Aug 2025 — SOU EXTENSION 5 GRANTED
- 14 May 2025 — SOU EXTENSION 5 FILED
- 14 May 2025 — SOU EXTENSION 5 FILED
- 14 May 2025 — SOU TEAS EXTENSION RECEIVED
- 22 Oct 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 22 Oct 2024 — SOU EXTENSION 4 GRANTED
- 22 Oct 2024 — SOU EXTENSION 4 FILED
- 22 Oct 2024 — SOU TEAS EXTENSION RECEIVED
- 15 May 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 14 May 2024 — SOU EXTENSION 3 GRANTED
- 14 May 2024 — SOU EXTENSION 3 FILED
- 14 May 2024 — SOU TEAS EXTENSION RECEIVED
- 21 Nov 2023 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED